Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azathioprine plus allopurinol versus azathioprine alone for inflammatory bowel disease
ACTRN12613001347752Phase 4Recruiting
- Sponsor
- Eastern Health
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of azathioprine, allopurinol and mercaptopurine in inflammatory bowel disease (IBD), Crohn's disease and autoimmune colitis (2 arms), sponsored by Eastern Health. Primary endpoint: Composite remission rate at week 26. Started Oct 2016; status: recruiting.
02
Drugs
azathioprineallopurinolmercaptopurine
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on ACTRN12613001347752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613001347752.